Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intrinsic Generation of Angular Momenta and Entanglement in Fission.

Physical review letters·2026
Same author

[Interstitial lung disease and primary Sjögren's syndrome combined with anti-AQP4 antibody-positive neuromyelitis optica spectrum disorder: a case report].

Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases·2026
Same author

[Survey on mosquito species diversity and pathogen spectrum of arbovirus in tropical regions of China].

Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi·2026
Same author

[Analysis of the comorbidity prevalence and related factors of elevated blood pressure and overweight and obesity in children aged 7-9 years in Zhejiang Province from 2018 to 2024].

Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]·2026
Same author

Dosimetric Predictors of Sexual Toxicity in Cervical Cancer Patients Treated With Definitive Chemoradiation and Magnetic Resonance Imaging-Guided Brachytherapy.

International journal of radiation oncology, biology, physics·2026
Same author

[Annual monitoring and analysis of airborne pollen in Chengdu urban area of Sichuan Province].

Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]·2026

Related Experiment Video

Updated: May 17, 2026

Adaptation of Semiautomated Circulating Tumor Cell (CTC) Assays for Clinical and Preclinical Research Applications
14:14

Adaptation of Semiautomated Circulating Tumor Cell (CTC) Assays for Clinical and Preclinical Research Applications

Published on: February 28, 2014

Continuity clinics in oncology training programs in Canada.

J M Croke1, M M Vickers, C E

  • 1The Ottawa Hospital Cancer Center, University of Ottawa, Ottawa, ON.

Current Oncology (Toronto, Ont.)
|November 13, 2012
PubMed
Summary

Continuity clinics (CCs) are valuable for oncology training in Canada, with most program directors and trainees finding them important. Patients, however, desire more supervision than trainees or directors anticipate.

Keywords:
Continuity clinicsmedical educationoncologyresidency training

More Related Videos

Radiation Planning Assistant - A Web-based Tool to Support High-quality Radiotherapy in Clinics with Limited Resources
05:18

Radiation Planning Assistant - A Web-based Tool to Support High-quality Radiotherapy in Clinics with Limited Resources

Published on: October 6, 2023

Differentiation of Mouse Breast Epithelial HC11 and EpH4 Cells
09:32

Differentiation of Mouse Breast Epithelial HC11 and EpH4 Cells

Published on: February 27, 2020

Related Experiment Videos

Last Updated: May 17, 2026

Adaptation of Semiautomated Circulating Tumor Cell (CTC) Assays for Clinical and Preclinical Research Applications
14:14

Adaptation of Semiautomated Circulating Tumor Cell (CTC) Assays for Clinical and Preclinical Research Applications

Published on: February 28, 2014

Radiation Planning Assistant - A Web-based Tool to Support High-quality Radiotherapy in Clinics with Limited Resources
05:18

Radiation Planning Assistant - A Web-based Tool to Support High-quality Radiotherapy in Clinics with Limited Resources

Published on: October 6, 2023

Differentiation of Mouse Breast Epithelial HC11 and EpH4 Cells
09:32

Differentiation of Mouse Breast Epithelial HC11 and EpH4 Cells

Published on: February 27, 2020

Area of Science:

  • Medical Education
  • Oncology
  • Clinical Practice

Background:

  • Continuity clinics (CCs) offer trainees longitudinal patient follow-up and semi-autonomous practice opportunities.
  • Data on the utility of CCs in Canadian oncology training programs are limited.

Purpose of the Study:

  • To assess the utility of continuity clinics in Canadian oncology training programs.
  • To evaluate the perspectives of program directors, trainees, and patients on CCs.

Main Methods:

  • Surveys were distributed electronically to medical and radiation oncology program directors and trainees.
  • Patient attitudes toward CCs were assessed via surveys at The Ottawa Hospital Cancer Centre.
  • Data were collected using SurveyMonkey and analyzed to determine participation rates and opinions.

Main Results:

  • 37% of trainees and 47% of program directors reported participation in CCs.
  • 80% of respondents deemed CCs "important" or "very important" for training.
  • Lack of clinic space was the primary challenge; patients desired more trainee supervision than anticipated.

Conclusions:

  • Continuity clinics are perceived as beneficial for oncology training by program directors and trainees.
  • Patient desire for increased trainee supervision in CCs is a key factor for implementation.
  • Balancing trainee autonomy with adequate patient supervision is crucial in CCs.